uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Uppsala University, Science for Life Laboratory, SciLifeLab.
2015 (English)In: Viruses, ISSN 1999-4915, E-ISSN 1999-4915, Vol. 7, no 11, 5780-5791 p.Article in journal (Refereed) Published
Abstract [en]

Immunostimulatory gene therapy has been developed during the past twenty years. The aim of immunostimulatory gene therapy is to tilt the suppressive tumor microenvironment to promote anti-tumor immunity. Hence, like a Trojan horse, the gene vehicle can carry warriors and weapons into enemy territory to combat the tumor from within. The most promising immune stimulators are those activating and sustaining Th1 responses, but even if potent effects were seen in preclinical models, many clinical trials failed to show objective responses in cancer patients. However, with new tools to control ongoing immunosuppression in cancer patients, immunostimulatory gene therapy is now emerging as an interesting option. In parallel, oncolytic viruses have been shown to be safe in patients. To prolong immune stimulation and to increase efficacy, these two fields are now merging and oncolytic viruses are armed with immunostimulatory transgenes. These novel agents are racing towards approval as established cancer immunotherapeutics.

Place, publisher, year, edition, pages
2015. Vol. 7, no 11, 5780-5791 p.
Keyword [en]
oncolytic; adenovirus; gene therapy; immunotherapy; tumor immunology
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-274204DOI: 10.3390/v7112899ISI: 000365656000009PubMedID: 26561829OAI: oai:DiVA.org:uu-274204DiVA: diva2:895985
Funder
Swedish Cancer SocietySwedish Research CouncilSwedish Childhood Cancer FoundationAFA Insurance
Available from: 2016-01-20 Created: 2016-01-20 Last updated: 2017-11-30Bibliographically approved

Open Access in DiVA

fulltext(1526 kB)148 downloads
File information
File name FULLTEXT01.pdfFile size 1526 kBChecksum SHA-512
ad45e278cb245485c81080af655af1934bda860bbea1531b4e3fba9b83297c82100f96502ddfd3089651ad9b53050b338a86e1c3bde6a847baffc74dd26d6029
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Loskog, Angelica

Search in DiVA

By author/editor
Loskog, Angelica
By organisation
Department of Immunology, Genetics and PathologyScience for Life Laboratory, SciLifeLab
In the same journal
Viruses
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 148 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 511 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf